Saturday, March 2, 2024
News

Study finds how new type of cell therapy help ARDS patients

   SocialTwist Tell-a-Friend    Print this Page   COMMENT

Los Angeles | February 11, 2024 11:54:32 PM IST
A novel form of cell therapy may help patients who are critically ill with acute respiratory distress syndrome (ARDS) brought on by severe COVID-19, according to a study.

Professor Justin Stebbing of Anglia Ruskin University (ARU) is a co-senior author of a recent study that examines the application of agenT-797, an allogeneic, unmodified invariant natural killer T (iNKT) cell treatment developed by MiNK Therapeutics.

The work was published in the journal Nature Communications.

The iNKT cell therapy has the effect of rescuing depleted T cells and inducing an anti-inflammatory cytokine response, perhaps activating antiviral immunity to assist these patients fight infection while also reducing severe, pathogenic inflammation of the lung.

The new research was carried out at three medical centres and found that agenT-797, which is also under investigation in cancer trials, could be manufactured rapidly, had a tolerable safety profile and appeared to have a positive effect on mortality among critically unwell COVID-19 ARDS patients receiving intensive care.

The exploratory trial included 20 mechanically ventilated patients with severe ARDS secondary to Covid-19. Of the 20 patients in the trial, 14 survived (70 per cent) at 30 days (compared to a control group of 10 per cent), and there was an 80 per cent lower occurrence of bacterial pneumonia amongst those who received the highest dosage of agenT-797, compared to those who received fewer cells.

Twenty-one patients were treated overall (the main trial, plus one under compassionate use), which included five who were also receiving veno-venous extracorporeal membrane oxygenation (VV-ECMO), known as 'the most aggressive salvage therapy' for critically ill patients with ARDS. In VV-ECMO, deoxygenated blood is pumped through a membrane lung and returned to the body via a cannula.

This trial is believed to be the first immune cell therapy of any type to be used in critically unwell patients undergoing VV-ECMO. Survival of the VV-ECMO cohort was 80 per cent after 30 and 90 days, and 60 per cent after 120 days. This compares favourably to the overall survival of 51 per cent for patients with Covid-19 who were treated with just VV-ECMO at the same institution, during the same timeframe.

Joint senior author Justin Stebbing, Professor of Biomedical Sciences at Anglia Ruskin University (ARU) in Cambridge, England, said, "During this small, exploratory study we observed that MiNK's iNKT cell treatment, which is also being advanced for people with cancer, triggered an anti-inflammatory response in ARDS patients.

"Despite a poor prognosis, critically ill patients treated with this therapy showed favourable mortality rates and those treated at the highest dose also had reduced rates of pneumonia, underscoring the potential application of iNKT cells, and agenT-797 in particular, in treating viral diseases and infections more broadly.

"AgenT-797 was manufactured rapidly and as opposed to using patients' cells, it is 'off-the-shelf' and made from healthy donors' cells. The potential of this therapy to be used across a number of severe infections warrants randomised controlled trials."

Dr Marc van Dijk, Chief Scientific Officer at MiNK and co-author of the study said, "These published findings reinforce the unique power and potential of iNKT cells to mitigate severe acute respiratory distress.

"The data demonstrate agenT-797's encouraging survival benefit, ability to help clear secondary infections, and tolerable administration in ventilated patients and those on VV-ECMO support." (ANI)

 
  LATEST COMMENTS ()
POST YOUR COMMENT
Comments Not Available
 
POST YOUR COMMENT
 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
 
MORE SCIENCE NEWS
Researchers find how anti-cancer drug ca...
Daylight saving time has minimal effect ...
Butterflies mimic each other's flight pa...
Vaping can enhance vulnerability to infe...
Study reveals how innovative chemotherap...
Researchers give insight into novel ther...
More...
 
INDIA WORLD ASIA
'India to produce 30 per cent of world's...
Rajasthan BJP chief CP Joshi announces n...
Mumbai Customs seize gold worth Rs 8.7 c...
TN Chief Election Officer flags off 'Ped...
Delhi witnesses sudden change in weather...
Lok Sabha Polls: Uttarakhand Chief Elect...
More...    
 
 Top Stories
Assam Rifles recover ammunition, 'w... 
Press Conference held In Mumbai Of ... 
JAIN: The Foremost Destination for ... 
NRAI lauds Indian Army for initiati... 
Huma Qureshi Inaugurates 4th UNCOVE... 
Kerala veterinary student's death: ... 
Union Minister Sonowal to inaugurat... 
"I have support of 80 per cent MLAs...